Celldex Therapeutics
CLDX
129 hedge funds and large institutions have $204M invested in Celldex Therapeutics in 2017 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 44 increasing their positions, 29 reducing their positions, and 17 closing their positions.
52% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 29
12% more capital invested
Capital invested by funds: $183M → $204M (+$21.5M)
8% more call options, than puts
Call options by funds: $904K | Put options by funds: $837K
6% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 17
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.17% less ownership
Funds ownership: 3.88% → 3.71% (-0.17%)
1% less funds holding
Funds holding: 130 → 129 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$4.21M |
| 2 |
AC
Ascend Capital
Orinda,
California
|
+$3.18M |
| 3 |
TCMG
TSP Capital Management Group
Summit,
New Jersey
|
+$2.9M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$1.79M |
| 5 |
MG
Meditor Group
Hamilton,
Bermuda
|
+$1.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
-$8.32M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.26M |
| 3 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$3.11M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.02M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.02M |
CLDX Hedge Fund Activity: Q3 2017 in Review
129 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q3 2017, worth a combined $204M — up 12% from $183M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new CLDX positions and 17 closed out — a net gain of 1 holder — while 44 added to existing stakes and 29 trimmed.
The largest buyer was Millennium Management, adding an estimated $4.21M. The largest seller was Columbia Wanger Asset Management, cutting an estimated $8.32M.
- 129 institutional investors held Celldex Therapeutics (CLDX) as of Q3 2017, down from 130 in Q2 2017.
- Funds reported $204M of Celldex Therapeutics stock for Q3 2017, up 12% quarter-over-quarter.
- 18 funds opened new Celldex Therapeutics positions in Q3 2017 and 17 closed out, a net change of +1 holder.
- The largest Celldex Therapeutics buyer in Q3 2017 was Millennium Management, an estimated $4.21M added.
- The largest Celldex Therapeutics seller in Q3 2017 was Columbia Wanger Asset Management, an estimated $8.32M sold.
Based on aggregated 13F filings for Q3 2017.